

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM582969

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
OXFORD FINANCE LLC, as Collateral Agent		06/24/2020	Limited Liability Company: DELAWARE

RECEIVING PARTY DATA

Name:	REATA PHARMACEUTICALS, INC.
Street Address:	5320 Legacy Drive
City:	Plano
State/Country:	TEXAS
Postal Code:	75024
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Serial Number:	86778681	REATA PHARMACEUTICALS
Serial Number:	86778679	REATA PHARMACEUTICALS
Serial Number:	86778689	REATA
Serial Number:	86778692	REATA
Serial Number:	86778686	
Serial Number:	88601911	ENMOVRY
Serial Number:	88601907	SKYLUMYS
Serial Number:	88601903	SKYCLARYS
Serial Number:	88601897	TREJOUVE
Serial Number:	88601892	ENDLYSSO
Serial Number:	88601887	ENDLYSSA

CORRESPONDENCE DATA

Fax Number: 4156932222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000

Email: crhem@cooley.com

Correspondent Name: Cooley LLP

Address Line 1: 101 California Street, 5th Floor

CH \$290.00 86778681

Address Line 4:	San Francisco, CALIFORNIA 94111
ATTORNEY DOCKET NUMBER:	313879-104
NAME OF SUBMITTER:	C. Rhem
SIGNATURE:	/CR/
DATE SIGNED:	06/24/2020
Total Attachments: 5 source=Reata-IP Security Interests Release Executed#page1.tif source=Reata-IP Security Interests Release Executed#page2.tif source=Reata-IP Security Interests Release Executed#page3.tif source=Reata-IP Security Interests Release Executed#page4.tif source=Reata-IP Security Interests Release Executed#page5.tif	

REASSIGNMENT AND RELEASE OF SECURITY INTEREST

This Reassignment and Release of Security Interest ("Release") is executed as of June 24, 2020, by OXFORD FINANCE LLC, a Delaware limited liability company, as collateral agent ("Assignor"), for the benefit of REATA PHARMACEUTICALS, INC., a Delaware corporation ("Assignee").

RECITALS

WHEREAS, Assignee granted and pledged certain security interests in the intellectual property described on Exhibit A and Exhibit B (together, the "Intellectual Property") to the Assignor pursuant to the Intellectual Property Security Agreement, dated as of June 14, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), and recorded with (a) the U.S. Patent and Trademark Office on June 14, 2018, at Reel/Frame 046357/0605, and on October 9, 2019, at Reel/Frame 050670/0902, with respect to patent security interests, and (b) the U.S. Patent and Trademark Office on June 14, 2018, at Reel/Frame 6353-0546, and on October 9, 2019, at Reel/Frame 6767/0489 with respect to trademark security interests; and

WHEREAS, Assignor wishes to release and reassign all interest that Assignor may have in the Intellectual Property as granted pursuant to the Security Agreement.

NOW, THEREFORE, IT IS AGREED THAT:

Assignor releases, discharges, terminates and cancels all of its security interest in and to the Intellectual Property arising under the Security Agreement, and reassigns to Assignee, without warranty or recourse, all interest of Assignor in the Intellectual Property granted pursuant to the Security Agreement.

ASSIGNOR:

OXFORD FINANCE LLC

Address:

133 North Fairfax Street
Alexandria, VA 22314
Attn: Legal Department


By: 
Name: Colette H. Featherly
Title: Senior Vice President

EXHIBIT A

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Methods of treating obesity using antioxidant inflammation modulations	13085338	4/12/11
Novel forms of CDDO methyl ester	8088824	1/3/12
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	7915402	3/29/11
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	7943778	5/17/11
Antioxidant inflammation modulators: novel derivatives of oleanolic acid	8071632	12/6/11
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	8124656	2/28/12
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	8124799	2/28/12
Dehydroandrosterone analogs including an anti- inflammatory pharmacore and methods of use	8258329	9/4/12
Novel forms of CDDO methyl ester	8309601	11/13/12
Antioxidant inflammation modulators: novel derivatives of oleanolic acid	8338618	12/25/12
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	8394967	3/12/13
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	8440820	5/14/13
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	8440854	5/14/13
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	8513436	8/20/13
Novel forms of CDDO methyl ester	8633243	1/21/14
Delayed release, oral dosage compositions that contain amorphous CDDO-ME	8747901	6/10/14
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	8993640	3/31/15
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	9090574	7/28/15
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	9102681	8/11/15
Delayed release, oral dosage compositions that contain amorphous CDDO-ME	9155721	10/13/15
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9174941	11/3/15
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	9233998	1/12/16

Description	Patent/App. No.	Issue/File Date
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	9249089	2/2/16
C13-hydroxy derivatives of oleanolic acid and methods of use thereof	9278912	3/8/16
C4 monomethyl triterpenoid derivatives and methods of use thereof	9290536	3/22/16
Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9464082	10/11/16
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	9512094	12/6/16
A-ring epoxidized triterpenoid-based antioxidant inflammation modulators and methods of use thereof	9556222	1/31/17
C17-alkanedyl and alkenedyl derivatives of oleanolic acid and methods of use thereof	9593074	3/14/17
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	9670147	6/6/17
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	9701709	7/11/17
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	9796668	10/24/17
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	15791677	10/24/17
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9884809	2/6/18
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	15861758	1/4/18
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	9889143	2/13/18
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	15861241	1/3/18
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	RE45288	12/9/14
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	RE45325	1/6/15
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof	14466495	8/22/14
C17-alkanedyl and alkenedyl derivatives of oleanolic acid and methods of use thereof	15433100	2/15/17
Imidazolyl tricyclic enones as antioxidant inflammation modulators	15548909	8/4/17
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	15615393	6/6/17
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	15622568	6/14/17
Synthetic triterpenoids and methods of use in the treatment of disease	8129429	3/6/12
Synthetic triterpenoids and methods of use in the treatment of disease	8455544	6/4/13
Synthetic triterpenoids and methods of use in the treatment of disease	9757359	9/12/17

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Synthetic triterpenoids and methods of use in the treatment of disease	15675862	8/14/17
Betulinic acid derivative and method of use thereof	8778990	7/15/14
C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses	15760662	3/16/18
RORgammaT inverse agonists with an Indazole or Hexahydroindazole core	62660859	4/20/18
RORgammaT inverse agonists with an Indazole or Hexahydroindazole core	62660865	4/20/18
Pyridopyrazolopyrimidine Derivatives for the Treatment of Cystic Fibrosis	62674549	5/21/18
Co-crystal Forms of a Novobiocin Analog and Proline	62627570	2/7/18
Biaryl Amides with Modified Sugar Groups for Treatment of Diseases Associated with Heat Shock Protein Pathway	62671047	5/14/18
Methods of treating Alport Syndrome using Bardoxolone Methyl or Analogs Thereof	62535663	7/21/17
Methods of treating Alport Syndrome using Bardoxolone Methyl or Analogs Thereof	62580597	11/2/17
Antioxidant inflammation modulators: oleanolic acid derivatived with amino and other modifications at c-17	16115028	8/28/18
Methods of treating obesity using antioxidant inflammation modulators	16130424	9/13/18
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof	16157225	10/11/18

EXHIBIT B

Trademarks

<u>Description</u>	<u>Serial No.</u>	<u>File Date</u>
REATA PHARMACEUTICALS	86778681	10/5/15
REATA PHARMACEUTICALS	86778679	10/5/15
REATA	86778689	10/5/15
REATA	86778692	10/5/15
Design	86778686	10/5/15
ENMOVRY	88601911	9/3/19
SKYLUMYS	88601907	9/3/19
SKYCLARYS	88601903	9/3/19
TREJOUVE	88601897	9/3/19
ENDLYSSO	88601892	9/3/19
ENDLYSSA	88601887	9/3/19